Treatment of metastatic breast cancer

What is this patent about?

’457 is related to the field of oncology and the targeted treatment of HER2-positive metastatic breast cancer. Specifically, it addresses the clinical challenge of improving survival outcomes for patients who have not yet received systemic chemotherapy or biologic therapy for their metastatic disease. While existing treatments like trastuzumab and taxanes have improved prognosis, metastatic breast cancer remains largely incurable, necessitating more aggressive and effective first-line intervention strategies.

The underlying idea behind ’457 is that a dual-antibody blockade targeting different regions of the HER2 receptor, when combined with a taxane, provides a synergistic therapeutic effect that significantly extends survival. By using one antibody to inhibit HER2 dimerization and another to inhibit growth through a separate epitope, the invention effectively shuts down multiple signaling pathways that drive tumor proliferation. Crucially, this intensified regimen is designed to be administered without increasing the risk of cardiac toxicity, a common concern in HER2-targeted therapies.

The claims of ’457 focus on a specific triple-combination regimen consisting of pertuzumab, trastuzumab, and docetaxel for previously untreated patients. The independent claims define a precise dosing schedule: pertuzumab is delivered as a fixed 840 mg loading dose followed by 420 mg maintenance doses; trastuzumab is weight-based at 8 mg/kg then 6 mg/kg; and docetaxel is administered starting at 75 mg/m² with a provision for escalation to 100 mg/m². The claims specifically require that this combination increases overall survival without increasing cardiac-specific adverse events or congestive heart failure compared to a two-drug regimen.

In practice, the invention is implemented as an intravenous infusion cycle repeated every three weeks. The treatment protocol allows for the escalation of the chemotherapy component if the patient demonstrates good tolerance, maximizing the cytotoxic impact while the antibodies maintain a continuous receptor blockade. This approach is particularly targeted at patients with a baseline left ventricular ejection fraction of at least 50%, ensuring that the heart's pumping capacity is sufficient to handle the potent therapeutic combination.

This invention differs from prior approaches by moving the combination of two different HER2-binding antibodies into the first-line setting for metastatic disease. Unlike earlier methods that used these agents sequentially or only after a patient failed initial therapy, ’457 demonstrates that early intervention with a comprehensive HER2 inhibition strategy provides a superior survival benefit. By standardizing the pertuzumab component as a fixed dose rather than weight-based, the invention also simplifies clinical administration while achieving the necessary therapeutic serum concentrations.